Mergers & Acquisitions ·
Edgewise Therapeutics, Inc. completed the acquisition of its muscular dystrophy program, including the sevasemten…
EWTXEdgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. completed the acquisition of its muscular dystrophy program, including the sevasemten compound and related assets, by Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, totaling a potential $2.65 billion. Edgewise Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for patients with muscular dystrophy and other rare diseases.